Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.425 -0.025 (-0.39%)
Streaming Delayed Price Updated: 11:04 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗
 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About ImmunityBio? ↗
 
Via Benzinga
News headline image
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
From ImmunityBio, Inc.
Via Business Wire
News headline image
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio ↗
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
Via Benzinga
News headline image
Texas Instruments Posts Strong Q3 Results, Joins Valmont Industries, Lithia Motors, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
ImmunityBio to Participate in the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
News headline image
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗
 
Via Benzinga
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024 ↗
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
News headline image
3 Top Cancer Treatment Stocks to Buy Now ↗
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
News headline image
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio? ↗
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
Via Benzinga
News headline image
Why ImmunityBio Stock Is Trading Higher Thursday ↗
The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments. 
Via Benzinga
News headline image
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
From ImmunityBio, Inc.
Via Business Wire
News headline image
3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions ↗
Don't be discouraged by the bears. Here are my three picks of short-squeeze stocks to buy for investors everywhere. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
From ImmunityBio, Inc.
Via Business Wire
News headline image
These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024 ↗
Economic slowdown meets short-selling speculations. Candidates for incoming market volatility are here. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.